Patents by Inventor Jinquan Luo

Jinquan Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190359705
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: May 29, 2019
    Publication date: November 28, 2019
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Patent number: 10450377
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 22, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Publication number: 20190270793
    Abstract: Monoclonal anti-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. The antibodies of the invention may also be used to quantify tau in biological samples.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 5, 2019
    Inventors: Kristof Van Kolen, Marc Mercken, Linda Barone, Eilyn R. Lacy, Rupesh Nanjunda, John Wheeler, Jinquan Luo
  • Patent number: 10358491
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 23, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Publication number: 20190202928
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: March 13, 2019
    Publication date: July 4, 2019
    Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
  • Publication number: 20190201527
    Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: March 20, 2019
    Publication date: July 4, 2019
    Inventors: Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill Giles-Komar, Jinquan Luo, Michael Rycyzyn, Raymond Sweet
  • Publication number: 20190135912
    Abstract: Broadly neutralizing interferon-? and interferon-? antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are usefule in the treatment of diseases associated with increased production of IFN? and IFN?.
    Type: Application
    Filed: November 8, 2018
    Publication date: May 9, 2019
    Applicant: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Publication number: 20190127444
    Abstract: The present disclosure is directed to staphylococcal leukotoxin and hemolysin binding molecules and fusion constructs. The present disclosure is further directed to methods of treating, preventing, and diagnosing staphylococcal infection in a subject using the binding molecules and fusion constructs described herein.
    Type: Application
    Filed: June 4, 2016
    Publication date: May 2, 2019
    Inventors: Randall J. BREZSKI, Anthony S. LYNCH, Peter T. BUCKLEY, Jeffrey FERNANDEZ, Jinquan LUO, Thomas J. MALIA, Sheng-Jiun WU, Victor J. TORRES
  • Patent number: 10273307
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 30, 2019
    Assignees: Biocerox Products B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
  • Patent number: 10272152
    Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: April 30, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill Giles-Komar, Jinquan Luo, Michael Rycyzyn, Raymond Sweet
  • Publication number: 20190106489
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 11, 2019
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Publication number: 20190085069
    Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Publication number: 20190062439
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: March 15, 2018
    Publication date: February 28, 2019
    Inventors: Karen DUFFY, Natalie Pursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Patent number: 10208113
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: February 19, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Patent number: 10155809
    Abstract: Broadly neutralizing interferon-? and interferon-? antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFN? and IFN?.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: December 18, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Publication number: 20180355061
    Abstract: Antibodies that specifically bind PD-1 or antigen binding fragments thereof, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of an inflammatory or immune disorder.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 13, 2018
    Inventors: Qiang Chen, Suzanne Cole, Karen Duffy, Yanxia Guo, Debra Gardner, Damon Hamel, Shannon Hitchcock, Ann Lacombe, Jinquan Luo, Ravi Malaviya, Yavegniya Orlovsky, Pejman Soroosh, Melissa Swiecki, Deepti Wilkinson
  • Publication number: 20180179294
    Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
  • Patent number: 9951137
    Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: April 24, 2018
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Karen Duffy, Natalie Fursov, LeRoy Hall, Catherine Healy, Roberta Lamb, Jinquan Luo, Ravi Malaviya, Michael Naso, Michael Pratta, Mark Tornetta, John Wheeler, Sheng-Jiun Wu
  • Patent number: 9932404
    Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 3, 2018
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
  • Publication number: 20180079809
    Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Application
    Filed: December 4, 2017
    Publication date: March 22, 2018
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy